Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207977249> ?p ?o ?g. }
- W3207977249 endingPage "4676" @default.
- W3207977249 startingPage "4665" @default.
- W3207977249 abstract "This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual disease (RD) after a predefined course of neoadjuvant chemotherapy and HER2-directed treatment are randomized 1:1 to adjuvant T-DM1 and placebo, versus T-DM1 and tucatinib. Patients have also received adjuvant radiotherapy and/or endocrine therapy, if indicated per standard of care guidelines. The primary objective of the trial is to determine if the invasive disease-free survival (iDFS) with T-DM1 plus tucatinib is superior to iDFS with T-DM1 plus placebo; other outcomes of interest include overall survival (OS), breast cancer-free survival (BCFS), distant recurrence-free survival (DRFS), brain metastases-free survival (BMFS) and disease-free survival (DFS). Correlative biomarker, quality of life (QoL) and pharmacokinetic (PK) end points are also evaluated." @default.
- W3207977249 created "2021-10-25" @default.
- W3207977249 creator A5001315712 @default.
- W3207977249 creator A5001562050 @default.
- W3207977249 creator A5008665323 @default.
- W3207977249 creator A5012303632 @default.
- W3207977249 creator A5026163032 @default.
- W3207977249 creator A5027090396 @default.
- W3207977249 creator A5032785430 @default.
- W3207977249 creator A5039694693 @default.
- W3207977249 creator A5040117135 @default.
- W3207977249 creator A5051532432 @default.
- W3207977249 creator A5052268581 @default.
- W3207977249 creator A5053783063 @default.
- W3207977249 creator A5058935870 @default.
- W3207977249 creator A5067365167 @default.
- W3207977249 creator A5074015095 @default.
- W3207977249 creator A5086581232 @default.
- W3207977249 creator A5090279568 @default.
- W3207977249 date "2021-12-01" @default.
- W3207977249 modified "2023-09-30" @default.
- W3207977249 title "Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer" @default.
- W3207977249 cites W1808104055 @default.
- W3207977249 cites W1988674313 @default.
- W3207977249 cites W1996778928 @default.
- W3207977249 cites W1996896645 @default.
- W3207977249 cites W2006070721 @default.
- W3207977249 cites W2040935952 @default.
- W3207977249 cites W2095633632 @default.
- W3207977249 cites W2095861620 @default.
- W3207977249 cites W2098775844 @default.
- W3207977249 cites W2111578514 @default.
- W3207977249 cites W2115759102 @default.
- W3207977249 cites W2120431466 @default.
- W3207977249 cites W2123591186 @default.
- W3207977249 cites W2146384083 @default.
- W3207977249 cites W2147415463 @default.
- W3207977249 cites W2154290856 @default.
- W3207977249 cites W2162982444 @default.
- W3207977249 cites W2221588520 @default.
- W3207977249 cites W2560406314 @default.
- W3207977249 cites W2585697071 @default.
- W3207977249 cites W2621988578 @default.
- W3207977249 cites W2624590002 @default.
- W3207977249 cites W2626331869 @default.
- W3207977249 cites W2742282063 @default.
- W3207977249 cites W2762153201 @default.
- W3207977249 cites W2768980003 @default.
- W3207977249 cites W2803163286 @default.
- W3207977249 cites W2810342468 @default.
- W3207977249 cites W2889673459 @default.
- W3207977249 cites W2902218997 @default.
- W3207977249 cites W2912357784 @default.
- W3207977249 cites W2942862617 @default.
- W3207977249 cites W2947111998 @default.
- W3207977249 cites W2973256872 @default.
- W3207977249 cites W2995808512 @default.
- W3207977249 cites W3015100763 @default.
- W3207977249 cites W3037488552 @default.
- W3207977249 cites W3056304265 @default.
- W3207977249 cites W3093646952 @default.
- W3207977249 cites W4239989216 @default.
- W3207977249 doi "https://doi.org/10.2217/fon-2021-0753" @default.
- W3207977249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8600597" @default.
- W3207977249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34636255" @default.
- W3207977249 hasPublicationYear "2021" @default.
- W3207977249 type Work @default.
- W3207977249 sameAs 3207977249 @default.
- W3207977249 citedByCount "7" @default.
- W3207977249 countsByYear W32079772492022 @default.
- W3207977249 countsByYear W32079772492023 @default.
- W3207977249 crossrefType "journal-article" @default.
- W3207977249 hasAuthorship W3207977249A5001315712 @default.
- W3207977249 hasAuthorship W3207977249A5001562050 @default.
- W3207977249 hasAuthorship W3207977249A5008665323 @default.
- W3207977249 hasAuthorship W3207977249A5012303632 @default.
- W3207977249 hasAuthorship W3207977249A5026163032 @default.
- W3207977249 hasAuthorship W3207977249A5027090396 @default.
- W3207977249 hasAuthorship W3207977249A5032785430 @default.
- W3207977249 hasAuthorship W3207977249A5039694693 @default.
- W3207977249 hasAuthorship W3207977249A5040117135 @default.
- W3207977249 hasAuthorship W3207977249A5051532432 @default.
- W3207977249 hasAuthorship W3207977249A5052268581 @default.
- W3207977249 hasAuthorship W3207977249A5053783063 @default.
- W3207977249 hasAuthorship W3207977249A5058935870 @default.
- W3207977249 hasAuthorship W3207977249A5067365167 @default.
- W3207977249 hasAuthorship W3207977249A5074015095 @default.
- W3207977249 hasAuthorship W3207977249A5086581232 @default.
- W3207977249 hasAuthorship W3207977249A5090279568 @default.
- W3207977249 hasBestOaLocation W32079772492 @default.
- W3207977249 hasConcept C121608353 @default.
- W3207977249 hasConcept C126322002 @default.
- W3207977249 hasConcept C142724271 @default.
- W3207977249 hasConcept C143998085 @default.
- W3207977249 hasConcept C204787440 @default.
- W3207977249 hasConcept C27081682 @default.
- W3207977249 hasConcept C530470458 @default.
- W3207977249 hasConcept C71924100 @default.